Using C3d Staining to Identify Complement-mediated Hemolytic Uremic Syndrome in Kidney Biopsies

Overview

About this study

The aim of this project is to evaluate whether kidney biopsy tissue will stain positive for C3d under immunofluorescence in patients who had renal thrombotic microangiopathy (TMA) caused by atypical hemolytic uremic syndrome (aHUS) and to study if that could offer a diagnostic value.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients with diagnoses of aHUS who had a kidney biopsy done in the past.

Exclusion Criteria:

Patient with TMA secondary to other causes rather than aHUS. Patients with aHUS who did not have a kidney biopsy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Sanjeev Sethi, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Sanjeev Sethi, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials